Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | ECE1 | P42892 | 2/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046493 | 0.87 | FOLH1 (0.42) | FOLH1MMEECE1NAALAD2SIRT2 | |
| SCHEMBL3037406 | 0.87 | FOLH1 (0.42) | FOLH1MMEECE1NAALAD2SIRT2 | |
| SCHEMBL3049456 | 0.85 | FOLH1 (0.39) | FOLH1MMEECE1NAALAD2SIRT2 | |
| SCHEMBL3054282 | 0.85 | MME (0.43) | FOLH1MMEECE1NAALAD2SIRT2 | |
| SCHEMBL3053901 | 0.84 | FOLH1 (0.40) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL3050998 | 0.83 | ECE1 (0.43) | FOLH1MMEECE1SIRT2SIRT1 | |
| SCHEMBL3040765 | 0.82 | ECE1 (0.38) | FOLH1MMEECE1SIRT2SIRT1 | |
| SCHEMBL3047963 | 0.81 | PPARA (0.41) | FOLH1MMENAALAD2PPARAPPARG | |
| SCHEMBL3043986 | 0.81 | LTA4H (0.39) | PPARA | |
| Trifluoroacetic Acid SCHEMBL3044628 | 0.81 | MME (0.42) | FOLH1MMEECE1NAALAD2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012153125-A1 | NOVEL COMPOUNDS AND METHODS FOR USE IN MEDICINE | ASTON UNIVERSITY (GB) | 2012-11-15 | — | — | WO | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | FOLH1 1880/4885MME 818/4885ECE1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.